Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Kalijn F. Bol; Hanneke W. Mensink; Erik H. J. G. Aarntzen; Gerty Schreibelt; Jan E. E. Keunen; Pierre G. Coulie; Annelies de Klein; Cornelis J. A. Punt; Dion Paridaens; Carl G. Figdor; I. Jolanda M. de Vries

doi:https://doi.org/10.1016/j.ajo.2014.07.014

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Kalijn F. Bol, Hanneke W. Mensink, Erik H. J. G. Aarntzen, Gerty Schreibelt, Jan E. E. Keunen, Pierre G. Coulie, Annelies de Klein, Cornelis J. A. Punt, Dion Paridaens, Carl G. Figdor, I. Jolanda M. de Vries

Research output: Contribution to journal › Article › Academic › peer-review

56 Citations (Scopus)

Abstract

To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. Interventional case series. We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma

Original language	English
Pages (from-to)	939-947
Journal	American Journal of Ophthalmology
Volume	158
Issue number	5
DOIs	https://doi.org/10.1016/j.ajo.2014.07.014
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/j.ajo.2014.07.014

Cite this

Bol, K. F., Mensink, H. W., Aarntzen, E. H. J. G., Schreibelt, G., Keunen, J. E. E., Coulie, P. G., de Klein, A., Punt, C. J. A., Paridaens, D., Figdor, C. G., & de Vries, I. J. M. (2014). Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. American Journal of Ophthalmology, 158(5), 939-947. https://doi.org/10.1016/j.ajo.2014.07.014

@article{98ae66bce52f44ddb2a959ea5766dff8,

title = "Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients",

abstract = "To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. Interventional case series. We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma",

author = "Bol, {Kalijn F.} and Mensink, {Hanneke W.} and Aarntzen, {Erik H. J. G.} and Gerty Schreibelt and Keunen, {Jan E. E.} and Coulie, {Pierre G.} and {de Klein}, Annelies and Punt, {Cornelis J. A.} and Dion Paridaens and Figdor, {Carl G.} and {de Vries}, {I. Jolanda M.}",

year = "2014",

doi = "https://doi.org/10.1016/j.ajo.2014.07.014",

language = "English",

volume = "158",

pages = "939--947",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

AU - Bol, Kalijn F.

AU - Mensink, Hanneke W.

AU - Aarntzen, Erik H. J. G.

AU - Schreibelt, Gerty

AU - Keunen, Jan E. E.

AU - Coulie, Pierre G.

AU - de Klein, Annelies

AU - Punt, Cornelis J. A.

AU - Paridaens, Dion

AU - Figdor, Carl G.

AU - de Vries, I. Jolanda M.

PY - 2014

Y1 - 2014

N2 - To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. Interventional case series. We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma

AB - To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. Interventional case series. We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma

U2 - https://doi.org/10.1016/j.ajo.2014.07.014

DO - https://doi.org/10.1016/j.ajo.2014.07.014

M3 - Article

C2 - 25038326

SN - 0002-9394

VL - 158

SP - 939

EP - 947

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 5

ER -